医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

HanAll Biopharma Co., Ltd. and Open Monoclonal Technology Announce Collaboration

2014年12月02日 AM01:03
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea & PALO ALTO, Calif.

HanAll BioPharma Co., Ltd. (HanAll), a public Korean biopharmaceutical company and leader in development of novel biologics and new chemical entities in immunology and oncology, and Open Monoclonal Technology, Inc. (OMT), an innovator in transgenic animals for the discovery of human therapeutic antibodies, today announced an alliance that provides HanAll with a license to use OMT’s OmniRat®, OmniMouse® and OmniFlic® platform for the generation of novel human antibodies against the Neonatal Fc Receptor (FcRn) and other undisclosed target antigens.

Dr. Seung Kook Park, CEO and Vice President of HanAll said, “We are pleased to enter into this strategic partnership with OMT. HanAll is committed to developing novel therapeutics that meet unmet medical needs and OMT’s transgenic animals will enable us to more rapidly create and develop novel therapeutic antibodies.”

Dr. Roland Buelow, founder and CEO of OMT, continued, “HanAll is a proven developer of human therapeutic antibodies and joins the group of international companies using OMT’s platforms as the first Korean partner. OMT looks forward to HanAll’s progress and the continued pursuit to make OmniRat, OmniMouse and OmniFlic preferred tools in therapeutic antibody discovery worldwide.”

About HanAll BioPharma Co., Ltd.

HanAll BioPharma Co. Ltd is a leading R&D-based biopharmaceutical company listed on the Korean Stock Exchange. HanAll has been developing innovative and unique biologics and NCEs in immunology and oncology for the global markets as follows;

HL161 is an anti-hFcRn monoclonal antibody as a new therapeutic option for the pathogenic IgG-medicated autoimmune diseases such as lupus nephritis, membranous nephropathy, pemphigus vulgaris, neuromyelitis optica and etc.

HL036 is a molecularly engineered soluble human TNF receptor I fragment formulated as an ophthalmic solution, with optimal properties for the treatment of dry eye disease.

HL176 are novel anti-cancer biguanide derivatives that inhibit mitochondrial OXPHOS and target cancer metabolism for the treatment of Braf inhibitors-resistant metastatic melanoma, MEK inhibitors-resistant NSCLC with Kras/LKB1 (-/-) mutation and other specific cancer type with mtDNA mutations.

HanAll is seeking strategic partnerships to accelerate the global clinical development of these pipelines.

About Open Monoclonal Technology, Inc.

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for creation of human therapeutic antibodies, naturally optimized human antibodies®, and the only company in the world with three transgenic animal platforms, OmniAb.

OmniRat® is the industry’s first human monoclonal antibody technology based on rats. OMT, in collaboration with Pfizer, has shown that OmniRat has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as well as a wild-type animals make rat antibodies. OmniMouse® is a transgenic mouse that complements OmniRat and expands epitope coverage. Both deliver human antibodies with high affinity, specificity, expression, solubility and stability. OmniFlic is the first engineered rat with a fixed light chain for development of bispecific, fully human antibodies.

OMT’s antibody platforms have broad freedom to operate and use technology protected by new patents and patent applications. They are available for licensing worldwide for all targets and indications. OMT has granted unlimited platform access to Genmab, Genentech, Janssen, Merck KGaA, Pfizer, Roche, Symphogen and an undisclosed global pharmaceutical company as well as individual target rights to smaller biotech and international companies. The Genentech partnership includes forward engineering of OmniRat that is made available to all OMT’s partners. OmniAb antibody discovery services are also available via US-based Antibody Solutions, Europe-based Aldevron and China-based WuXi AppTec.

For more information, please visit www.hanallbiopharma.com or www.omtinc.net or contact:

CONTACT

HanAll Korea (HQ)
Soonim Lee, +82-2-2204-1753
Director,
Business Development
silee@hanall.co.kr
or
HanAll
US (HPI)
Seungtaek Oh, +1-301-738-3980
Director, Business
Development
stoh@hanall.co.kr
or
Open
Monoclonal Technology, Inc.
Brian Lundstrom, +1-775-420-7750
Chief
Business Officer
bl@omtinc.net

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent